New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
07:16 EDTLLY, PFEEli Lilly: FY14 guidance doesn't include potential charge related to Pfizer deal
The company's 2014 financial guidance does not include a potential charge related to the collaboration with Pfizer (PFE) to develop and commercialize tanezumab. As previously communicated, if the partial clinical hold for the molecule is removed and Lilly (LLY) and Pfizer move forward with development, Lilly will pay a $200M upfront fee to Pfizer. This charge would cause Lilly's GAAP tax rate to be roughly 1 percentage point lower than its non-GAAP tax rate and would reduce GAAP EPS by approximately 12c.
News For LLY;PFE From The Last 14 Days
Check below for free stories on LLY;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
05:57 EDTLLYEli Lilly upgraded to Hold from Underperform at Jefferies
Subscribe for More Information
April 11, 2014
07:19 EDTPFEAcura Pharma to host conference call
Subscribe for More Information
April 10, 2014
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
April 9, 2014
08:03 EDTLLYEli Lilly and T1D to partner in diabetes research collaboration
Subscribe for More Information
April 8, 2014
11:03 EDTPFE, LLYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
10:03 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTLLYEli Lilly to challenge verdict in Terrence Allen, et al. v. Takeda case
Subscribe for More Information
08:39 EDTLLYTakeda to challenge award of $6B in punitive damages, Lilly ordered to pay $3B
Takeda Pharmaceuticals (TKPYY) announced last night that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America the jury found in favor of the plaintiffs and awarded $1.475M in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly (LLY). The jury also awarded $6B in punitive damages from Takeda and $3B from co-defendant, Eli Lilly. “Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal. We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS,” said Kenneth Greisman, senior vice president, general counsel, Takeda. Reference Link
08:26 EDTLLYEli Lilly upgraded at BMO Capital
Subscribe for More Information
06:24 EDTLLYEli Lilly upgraded to Market Perform from Underperform at BMO Capital
Subscribe for More Information
April 7, 2014
17:28 EDTPFEPfizer sell-off unwarranted, Barron's says
Subscribe for More Information
16:28 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
12:15 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTPFEPfizer trades near lows of the day, levels to watch
Subscribe for More Information
09:10 EDTPFEOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:09 EDTPFEConfusion on Pfizer Palbo could create buying opportunity, says BMO Capital
Subscribe for More Information
09:00 EDTPFEPfizer falls 2.8%
Pfizer is down 2.8%, or 90c, to $31.25
07:27 EDTPFEAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
April 6, 2014
13:57 EDTLLYLilly to present data from bemaciclib as potential treatment for breast cancer
Subscribe for More Information
13:46 EDTPFEPfizer's palbociclib significantly prolonged PFS in metastatic breast cancer
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use